Inhibitors of prototypic galectin dimerization and uses thereof
AssigneeInstitut National De La Recherche Scientifique
InventorsDavid Chatenet, Nicolas Doucet, Yves St-Pierre, Maria-Claudia Vladoiu
Life of this patent
Estimating the term…
Abstract
Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7. The use of such agents to inhibit a biological, physiological and/or pathological process that involves prototypic galectin dimerization, for example for the inhibition of galectin-7-mediated apoptosis and the treatment of galectin-7-expressing cancers, is also described.
Claims19
A peptide which is of one of the following sequences:
- Leu-Asp-Ser-Val-Arg-Ile-Phe-NH2 (SEQ ID NO:2), Ile-Arg-Pro-Gly-Thr-Val-Leu-Arg-Gly-Leu-Val-NH2 (SEQ ID NO:4), Asp-Gly-Phe-Lys-Ala-Val-Val-Gly-Asp-Ala-Gln-Tyr-His-His-NH2 (SEQ ID NO:6) or Phe-Glu-Val-Leu-Ile-Ile-Ala-Ser-Asp-Asp-Gly-Phe-Lys-Ala-Val-Val-Gly-NH2 (SEQ ID NO:8), or a salt thereof.
Dependencies are inferred from the claim text.